in the vicinity of King’s Cross, and that around 40 workers will be based at the site from Novo Nordisk’s R&D and IT divisions. The KQ cluster is in close proximity to major institutions at ...

Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time ...

Meanwhile, Novo Nordisk shares in Copenhagen closed 1.34% lower, taking the company’s market value just under 2.33 trillion Danish kroner ($337.79 billion).

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...

Novo Nordisk has signed a deal with AI-driven protein design company Gensaic to develop tissue-targeted therapies for cardiometabolic diseases. The collaboration is valued up to $354m, but ...

Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop ...